A Monotherapy Study to Evaluate the Efficacy and Safety of 2 Dose Levels of Albiglutide in Japanese Subjects With Type 2 Diabetes Mellitus (T2DM)

A Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multicenter Monotherapy Study to Determine the Efficacy and Safety of 2 Dose Levels of Albiglutide in Subjects With Type 2 Diabetes Mellitus

This study is designed to examine the efficacy and safety of 2 dose levels of weekly subcutaneously injected albiglutide compared with placebo and an open label reference arm of daily subcutaneous injections of liraglutide, in Japanese subjects with Type 2 diabetes mellitus.

Study Overview

• Status: Completed
• Conditions: Diabetes Mellitus, Type 2
• Intervention / Treatment: Drug: Albiglutide 30 mg weekly; Drug: Placebo; Drug: Albiglutide 50 mg weekly; Drug: Liraglutide 0.9 mg daily

• Study Type: Interventional
• Enrollment (Actual): 494
• Phase: Phase 3

Contacts and Locations

Study Locations

• Japan
  • Aichi, Japan, 456-0058
    • GSK Investigational Site
  • Chiba, Japan, 263-0043
    • GSK Investigational Site
  • Ehime, Japan, 792-8586
    • GSK Investigational Site
  • Ehime, Japan, 790-0067
    • GSK Investigational Site
  • Ehime, Japan, 792-0045
    • GSK Investigational Site
  • Fukuoka, Japan, 819-0168
    • GSK Investigational Site
  • Fukuoka, Japan, 810-0014
    • GSK Investigational Site
  • Fukuoka, Japan, 815-8588
    • GSK Investigational Site
  • Fukuoka, Japan, 812-0053
    • GSK Investigational Site
  • Fukushima, Japan, 960-0418
    • GSK Investigational Site
  • Fukushima, Japan, 963-8851
    • GSK Investigational Site
  • Fukushima, Japan, 961-0416
    • GSK Investigational Site
  • Fukushima, Japan, 964-8501
    • GSK Investigational Site
  • Gunma, Japan, 370-3573
    • GSK Investigational Site
  • Gunma, Japan, 379-0116
    • GSK Investigational Site
  • Hiroshima, Japan, 731-0103
    • GSK Investigational Site
  • Hokkaido, Japan, 040-8585
    • GSK Investigational Site
  • Hokkaido, Japan, 070-0002
    • GSK Investigational Site
  • Hokkaido, Japan, 062-0007
    • GSK Investigational Site
  • Hokkaido, Japan, 072-0012
    • GSK Investigational Site
  • Hokkaido, Japan, 080-0010
    • GSK Investigational Site
  • Hokkaido, Japan, 080-0016
    • GSK Investigational Site
  • Hyogo, Japan, 670-0074
    • GSK Investigational Site
  • Ibaraki, Japan, 311-0113
    • GSK Investigational Site
  • Ibaraki, Japan, 300-0835
    • GSK Investigational Site
  • Ibaraki, Japan, 300-1512
    • GSK Investigational Site
  • Kagawa, Japan, 760-0076
    • GSK Investigational Site
  • Kagawa, Japan, 760-0017
    • GSK Investigational Site
  • Kagoshima, Japan, 890-0061
    • GSK Investigational Site
  • Kanagawa, Japan, 212-0024
    • GSK Investigational Site
  • Kanagawa, Japan, 232-0064
    • GSK Investigational Site
  • Kanagawa, Japan, 235-0045
    • GSK Investigational Site
  • Kanagawa, Japan, 253-0044
    • GSK Investigational Site
  • Kanagawa, Japan, 238-0011
    • GSK Investigational Site
  • Kanagawa, Japan, 242-0004
    • GSK Investigational Site
  • Kochi, Japan, 780-0088
    • GSK Investigational Site
  • Kumamoto, Japan, 862-0976
    • GSK Investigational Site
  • Kumamoto, Japan, 867-0041
    • GSK Investigational Site
  • Kumamoto, Japan, 866-8660
    • GSK Investigational Site
  • Kyoto, Japan, 601-1495
    • GSK Investigational Site
  • Kyoto, Japan, 600-8558
    • GSK Investigational Site
  • Miyagi, Japan, 980-0021
    • GSK Investigational Site
  • Miyagi, Japan, 985-0852
    • GSK Investigational Site
  • Nagano, Japan, 399-0006
    • GSK Investigational Site
  • Nagano, Japan, 399-0036
    • GSK Investigational Site
  • Nagano, Japan, 385-0022
    • GSK Investigational Site
  • Nara, Japan, 634-0007
    • GSK Investigational Site
  • Oita, Japan, 870-0039
    • GSK Investigational Site
  • Oita, Japan, 876-0851
    • GSK Investigational Site
  • Okinawa, Japan, 901-0243
    • GSK Investigational Site
  • Osaka, Japan, 530-0012
    • GSK Investigational Site
  • Osaka, Japan, 530-0001
    • GSK Investigational Site
  • Osaka, Japan, 577-0803
    • GSK Investigational Site
  • Osaka, Japan, 536-0023
    • GSK Investigational Site
  • Osaka, Japan, 538-0044
    • GSK Investigational Site
  • Osaka, Japan, 532-0026
    • GSK Investigational Site
  • Osaka, Japan, 530-0004
    • GSK Investigational Site
  • Saitama, Japan, 332-0012
    • GSK Investigational Site
  • Saitama, Japan, 350-0035
    • GSK Investigational Site
  • Saitama, Japan, 350-0851
    • GSK Investigational Site
  • Saitama, Japan, 354-0031
    • GSK Investigational Site
  • Saitama, Japan, 355-0321
    • GSK Investigational Site
  • Saitama, Japan, 358-0011
    • GSK Investigational Site
  • Shizuoka, Japan, 424-0855
    • GSK Investigational Site
  • Tochigi, Japan, 329-0433
    • GSK Investigational Site
  • Tokyo, Japan, 103-0027
    • GSK Investigational Site
  • Tokyo, Japan, 103-0028
    • GSK Investigational Site
  • Tokyo, Japan, 125-0054
    • GSK Investigational Site
  • Tokyo, Japan, 104-0031
    • GSK Investigational Site
  • Tokyo, Japan, 103-0002
    • GSK Investigational Site
  • Tokyo, Japan, 143-0015
    • GSK Investigational Site
  • Tokyo, Japan, 136-0073
    • GSK Investigational Site
  • Tokyo, Japan, 104-0061
    • GSK Investigational Site
  • Yamaguchi, Japan, 755-0047
    • GSK Investigational Site

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 20 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

• Subjects with diagnosis of Type 2 Diabetes Mellitus, treated with diet and exercise or a stable dose of 1 OAD at screening
• Body mass index (BMI) 17 to 40 kg/ m^2 inclusive
• Subjects who are OAD naïve, HbA1c between 7.0% and 10.0% at Screening and at Visit 2; for subjects who enter the study with 1 OAD, HbA1c between 6.5% and 9.5% at Screening and HbA1c between 7.0% and 10.0% at Visit 2
• Creatinine clearance >30 mL/min (calculated using the Cockcroft-Gault formula)

Exclusion Criteria:

• History of type 1 diabetes mellitus •Female subject is pregnant, lactating, or <6 weeks postpartum•
• Clinically significant cardiovascular and/or cerebrovascular disease
• Current ongoing symptomatic biliary disease, clinical signs or symptoms of pancreatitis, or a history of chronic or acute pancreatitis, as determined by the investigator
• Serum amylase >=3 ×ULN and/or serum lipase >=2 × ULN and/or subject is experiencing any symptoms possibly related to pancreatitis
• Prior use of a TZD or GLP-1R agonist within 4 months before Screening

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Double

Number of Arms

4

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Albiglutide 30 mg weekly; Subjects will be randomly assigned to double blind albiglutide 30 mg weekly treatment for 52 weeks	Drug: Albiglutide 30 mg weekly; Albiglutide will be available as a pen injector that delivers 30mg of albiglutide; Drug: Placebo; Albiglutide matching placebo will be available as a pen injector
Experimental: Albiglutide 50 mg weekly; Subjects will be randomly assigned to double blind albiglutide 50 mg weekly until Week 52	Drug: Albiglutide 50 mg weekly; Albiglutide will be available as a pen injector that delivers 50mg of albiglutide
Placebo Comparator: Placebo; Subjects will be randomly assigned to double blind matching albiglutide placebo administered weekly. Subjects will then cross-over to double-blind treatment with albiglutide 30 mg weekly at Week 24 until Week 52	Drug: Placebo; Albiglutide matching placebo will be available as a pen injector
Active Comparator: Liraglutide 0.9 mg daily; Subjects will be randomly assigned to open-label liraglutide for 52 weeks	Drug: Liraglutide 0.9 mg daily; Liraglutide will be available as prefilled multidose pens that can deliver 0.9 mg dose

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Model-adjusted Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 24	HbA1c is a form of hemoglobin that is measured primarily to identify the average plasma glucose concentration over a 2- to 3 month period. The Baseline HbA1c value is defined as the last nonmissing value before the start of treatment. Change from Baseline was calculated as the value at Week 24 minus the value at Baseline. Based on analysis of covariance (ANCOVA): Change at Week 24 = treatment (placebo, albiglutide 30 mg, albiglutide 50 mg) + Baseline HbA1c + prior diabetes therapy + age category (<65 years versus ≥65 years). Participants who discontinued from study treatment before Week 24 had their last post-Baseline HbA1c carried forward for the analysis unless the value is past 14 days after the last dose of study drug. The open-label liraglutide group was a reference group and not included in the primary endpoint analysis model. Descriptive summary statistics are provided as a separate outcome measure.	Baseline and Week 24
Mean HbA1c at Baseline, Week 24, and Change From Baseline at Week 24	HbA1c is a form of hemoglobin that is measured primarily to identify the average plasma glucose concentration over a 2- to 3 month period. The Baseline HbA1c value is defined as the last nonmissing value before the start of treatment. Change from Baseline was calculated as the value at Week 24 minus the value at Baseline. Participants who discontinued from study treatment before Week 24 had their last post-Baseline HbA1c value carried forward for the summary, unless the value was past 14 days after the last dose of study drug. The open-label liraglutide group was a reference group; descriptive statistics comparing albiglutide and liraglutide were exploratory endpoints.	Baseline and Week 24

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Change From Baseline in HbA1c at Week 52	HbA1c is a form of hemoglobin that is measured primarily to identify the average plasma glucose concentration over a 2- to 3- month period. The Baseline HbA1c value is defined as the last non-missing value on or before the start of treatment. Change from Baseline was calculated as the value at Week 52 minus the value at Baseline.	Baseline and Week 52
Percentage of Participants Achieving Clinically Meaningful Levels of HbA1c (i.e., the Percentage of Participants Achieving Treatment Goal of <6.5% and <7.0%) at Week 24	HbA1c is a form of hemoglobin that is measured primarily to identify the average plasma glucose concentration over a 2- to 3 month period. Clinically meaningful levels of response in HbA1c are defined as <6.5% and <7.0%. Participants who discontinued the study before Week 24 had their last post-Baseline HbA1c value carried forwrad for the summary unless the value was past 14 days after the last dose of study drug.	Week 24
Percentage of Participants Achieving Clinically Meaningful Levels of HbA1c (i.e., the Percentage of Participants Achieving Treatment Goal of <6.5% and <7.0%) at Week 52	HbA1c is a form of hemoglobin that is measured primarily to identify the average plasma glucose concentration over a 2- to 3 month period. Clinically meaningful levels of response in HbA1c are defined as <6.5% and <7.0%.	Week 52
Change From Baseline in Fasting Plasma Glucose (FPG) at Week 24	FPG is an indicator of efficacy. The Baseline FPG value is defined as the last non-missing value before the start of treatment. Change from Baseline was calculated as the FPG value at Week 24 minus the FPG value at Baseline. Participants who discontinued from study treatment before Week 24 had their last post-Baseline FPG observation carried forward for the summary unless the value was 14 days past the last dose of study drug.	Baseline and Week 24
Change From Baseline in Fasting Plasma Glucose (FPG) at Week 52	FPG is an indicator of efficacy. The Baseline FPG value is defined as the last non-missing value on or before the start of treatment. Change from Baseline was calculated as the FPG value at Week 52 minus the FPG value at Baseline.	Baseline and Week 52
Change From Baseline in Body Weight at Week 24	The Baseline body weight value is defined as the last non-missing value before the start of treatment. Change from Baseline was calculated as the body weight value at Week 24 minus the value at Baseline. Participants who discontinued from the study treatment before Week 24 had their last non-missing weight carried forward for the summary, unless the value is past 14 days after the last dose of study drug.	Baseline and Week 24
Change From Baseline in Body Weight at Week 52	The Baseline body weight value is defined as the last non-missing value before the start of treatment. Change from Baseline was calculated as the body weight value at Week 52 minus the value at Baseline.	Baseline and Week 52
Time to Study Withdrawal Due to Hyperglycemia	Participants who experienced persistent hyperglycemia after uptitration were to be withdrawn from the study. Hyperglycemia is defined as a fasting plasma glucose (FPG) ≥280 mg/dL (≥15.5 mmol/L) from ≥Week 2 to <Week 4, ≥250 mg/dL (≥13.9 mmol/L) from ≥Week 4 to <Week 12, or ≥230 mg/dL (≥12.8 mmol/L) from ≥Week 12 to <Week 52, confirmed a second evaluation within 7 days.	Baseline through Week 52
Time to Study Withdrawal for Any Reason	Time to withdrawal was calculated as the number of days between the date of first dose and the date of withdrawal plus 1. Time to withdrawal was summarized by visit.	Baseline through Week 52

Collaborators and Investigators

• Sponsor: GlaxoSmithKline

Publications and helpful links

Helpful Links

• Researchers can use this site to request access to anonymised patient level data and/or supporting documents from clinical studies to conduct further research.

Study record dates

Study Major Dates

• Study Start: February 1, 2013
• Primary Completion (Actual): June 1, 2014
• Study Completion (Actual): February 1, 2015

Study Registration Dates

• First Submitted: November 21, 2012
• First Submitted That Met QC Criteria: November 21, 2012
• First Posted (Estimate): November 27, 2012

Study Record Updates

• Last Update Posted (Estimate): September 22, 2016
• Last Update Submitted That Met QC Criteria: August 12, 2016
• Last Verified: August 1, 2016

More Information

Terms related to this study

• Keywords: Japanese; Type 2 diabetes mellitus; albiglutide; GSK716155; glucagon-like peptide 1
• Additional Relevant MeSH Terms: Glucose Metabolism Disorders; Metabolic Diseases; Endocrine System Diseases; Diabetes Mellitus; Diabetes Mellitus, Type 2; Hypoglycemic Agents; Physiological Effects of Drugs; Hormones; Hormones, Hormone Substitutes, and Hormone Antagonists; Incretins; Liraglutide; rGLP-1 protein; Glucagon-Like Peptide 1
• Other Study ID Numbers: 113121

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: YES
• IPD Plan Description: Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.

Study Data/Documents

1. Dataset Specification
   Information identifier: 113121
   Information comments: For additional information about this study please refer to the GSK Clinical Study Register
2. Annotated Case Report Form
   Information identifier: 113121
   Information comments: For additional information about this study please refer to the GSK Clinical Study Register
3. Individual Participant Data Set
   Information identifier: 113121
   Information comments: For additional information about this study please refer to the GSK Clinical Study Register
4. Clinical Study Report
   Information identifier: 113121
   Information comments: For additional information about this study please refer to the GSK Clinical Study Register
5. Study Protocol
   Information identifier: 113121
   Information comments: For additional information about this study please refer to the GSK Clinical Study Register
6. Informed Consent Form
   Information identifier: 113121
   Information comments: For additional information about this study please refer to the GSK Clinical Study Register
7. Statistical Analysis Plan
   Information identifier: 113121
   Information comments: For additional information about this study please refer to the GSK Clinical Study Register